Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13056746 | 1.00 | ACKR3 (0.60) | ACKR3KDM4EPKMKMT2AALDH1A1 | |
| SCHEMBL3126505 | 0.87 | KDM4E (0.79) | KDM4EPKMKMT2AALDH1A1LMNA | |
| SCHEMBL16333276 | 0.85 | ACKR3 (0.57) | ACKR3ALDH1A1KDM1ABACE1CTSD | |
| SCHEMBL3124563 | 0.83 | ALDH1A1 (0.58) | KDM4EKMT2AALDH1A1LMNATPSAB1 | |
| SCHEMBL14731327 | 0.83 | KDM4E (0.69) | ACKR3KDM4EPKMKMT2ALMNA | |
| SCHEMBL3448188 | 0.83 | KDM4E (0.69) | ACKR3KDM4EPKMKMT2AALDH1A1 | |
| SCHEMBL3448190 | 0.83 | KDM4E (0.69) | ACKR3KDM4EPKMKMT2AALDH1A1 | |
| SCHEMBL3448205 | 0.82 | KDM4E (0.67) | ACKR3KDM4EPKMKMT2AALDH1A1 | |
| SCHEMBL3448200 | 0.82 | KDM4E (0.67) | ACKR3KDM4EPKMKMT2AALDH1A1 | |
| SCHEMBL13056742 | 0.81 | USP30 (0.66) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170849-B1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-9187465-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-8921544-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2014-12-30 | — | — | US | disclosed |
| US-20140275041-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20130102592-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-8378095-B2 | Oxazole tyrosine kinase inhibitors | Saruem Limited (GB) | 2013-02-19 | — | — | US | disclosed |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275041-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | ACKR3 1964/4885KDM4E 718/4885PKM 921/4885 |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | ACKR3 1964/4885KDM4E 718/4885PKM 921/4885 |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | ACKR3 1964/4885KDM4E 718/4885PKM 921/4885 |
| US-20130102592-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | ACKR3 1771/4885KDM4E 675/4885PKM 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.